KBC Group NV Has $2.21 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

KBC Group NV cut its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after selling 11,944 shares during the quarter. KBC Group NV's holdings in Natera were worth $2,207,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after buying an additional 2,036,396 shares during the last quarter. Norges Bank acquired a new stake in shares of Natera in the 4th quarter valued at approximately $224,040,000. Raymond James Financial Inc. acquired a new stake in shares of Natera in the 4th quarter valued at approximately $146,419,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada initiated coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. Barclays upped their price objective on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Piper Sandler raised their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Trading Down 0.0%

NTRA stock traded down $0.07 during trading hours on Friday, hitting $161.50. 468,868 shares of the stock were exchanged, compared to its average volume of 1,425,063. The firm has a market capitalization of $22.05 billion, a P/E ratio of -109.86 and a beta of 1.73. The company has a 50-day simple moving average of $160.34 and a two-hundred day simple moving average of $158.44. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.56) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the sale, the chief executive officer directly owned 185,182 shares in the company, valued at $27,795,818.20. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,272 shares of company stock worth $8,345,368. Company insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.